Description

Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C65H104N18O26S4—-[1]Shailubhai K,et, al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):213-22.|[2]Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2018 Jun 8;11:1756284818777945.|[3]Shailubhai K, et, al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe. Dig Dis Sci. 2013 Sep;58(9):2580-6.–467426-54-6–1681.89–98.14–NC(C[C@H](N)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H]1C(N[C@H](C(N[C@H](C(N[C@]2([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@@](C(NCC(N[C@@H](CSSC2)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)([H])[C@H](O)C)=O)([H])CSSC1)=O)C)=O)C(C)C)=O)CC(N)=O)=O)C(C)C)=O)=O)CC(C)C)=O)CCC(O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–DMSO : 100 mg/mL (ultrasonic)–Guanylate Cyclase—-GPCR/G Protein–Peptides